Literature DB >> 22248195

Overview of regular dialysis treatment in Japan (as of 31 December 2009).

Shigeru Nakai1, Kunitoshi Iseki, Noritomo Itami, Satoshi Ogata, Junichiro James Kazama, Naoki Kimata, Takashi Shigematsu, Toshio Shinoda, Tetsuo Shoji, Kazuyuki Suzuki, Masatomo Taniguchi, Kenji Tsuchida, Hidetomo Nakamoto, Hiroshi Nishi, Seiji Hashimoto, Takeshi Hasegawa, Norio Hanafusa, Takayuki Hamano, Naohiko Fujii, Ikuto Masakane, Seiji Marubayashi, Osamu Morita, Kunihiro Yamagata, Kenji Wakai, Atsushi Wada, Yuzo Watanabe, Yoshiharu Tsubakihara.   

Abstract

A nationwide statistical survey of 4196 dialysis facilities was conducted at the end of 2009, and 4133 facilities (98.5%) responded. The number of patients undergoing dialysis at the end of 2009 was determined to be 290 661, an increase of 7240 patients (2.6%) compared with that of 2008. The number of dialysis patients per million at the end of 2009 was 2279.5. The crude death rate of dialysis patients from the end of 2008 to the end of 2009 was 9.6%. The mean age of the new patients introduced into dialysis was 67.3 years old and the mean age of the entire dialysis patient population was 65.8 years old. Primary diseases such as diabetic nephropathy and chronic glomerulonephritis for new dialysis patients, showed a percentage of 44.5% and 21.9%, respectively. Based on the facilities surveyed, 84.2% of the facilities that responded to the questionnaire satisfied the microbiological quality standard for dialysis fluids for the Japanese Society for Dialysis Therapy (JSDT), with an endotoxin concentration of less than 0.05 EU/mL in the dialysis fluid. Similarly, 98.2% of the facilities surveyed satisfied another standard of the society of a bacterial count of less than 100 cfu/mL in the dialysis fluid. The facility survey indicated that the number of patients who were treated by blood purification by both peritoneal dialysis and extracorporeal circulation, such as hemodialysis, was 1720. Among the total number of patients, 24.8% were satisfied with the management target recommended in the treatment guidelines for secondary hyperparathyroidism. These standards are set by the JSDT, based on the three parameters, i.e. serum calcium concentration, serum phosphorus concentration, and serum intact parathyroid hormone concentration. According to the questionnaire, 9.8% of the patients were considered to have a complication of dementia.
© 2012 The Authors. Therapeutic Apheresis and Dialysis © 2012 International Society for Apheresis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22248195     DOI: 10.1111/j.1744-9987.2011.01050.x

Source DB:  PubMed          Journal:  Ther Apher Dial        ISSN: 1744-9979            Impact factor:   1.762


  26 in total

1.  Safety of warfarin therapy in chronic hemodialysis patients: a prospective cohort study.

Authors:  Matsuhiko Hayashi; Takayuki Abe; Mieko Iwai; Ayumi Matsui; Tadashi Yoshida; Yuji Sato; Yoshihiko Kanno
Journal:  Clin Exp Nephrol       Date:  2015-12-01       Impact factor: 2.801

2.  Stiffness parameter β as a predictor of the 4-year all-cause mortality of chronic hemodialysis patients.

Authors:  Masayo Sato; Tetsuya Ogawa; Kuniaki Otsuka; Yoshitaka Ando; Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2012-08-02       Impact factor: 2.801

3.  A case of disseminated tuberculosis after the initiation of hemodialysis.

Authors:  Jumpei Hasegawa; Sachiko Wakai
Journal:  CEN Case Rep       Date:  2013-04-10

4.  Views of Japanese patients on the advantages and disadvantages of hemodialysis and peritoneal dialysis.

Authors:  Nanako Nakamura-Taira; Yoshimi Muranaka; Masako Miwa; Seikon Kin; Kei Hirai
Journal:  Int Urol Nephrol       Date:  2012-11-16       Impact factor: 2.370

5.  Clinical factors associated with serum copper levels and potential effect of sevelamer in hemodialysis patients.

Authors:  Ryota Ikee; Masataka Tsunoda; Naomi Sasaki; Naritsugu Sato; Nobuo Hashimoto
Journal:  Int Urol Nephrol       Date:  2012-06-09       Impact factor: 2.370

6.  Survival after arterial embolization therapy in patients with polycystic kidney and liver disease.

Authors:  Junichi Hoshino; Tatsuya Suwabe; Noriko Hayami; Keiichi Sumida; Koki Mise; Masahiro Kawada; Aya Imafuku; Rikako Hiramatsu; Masayuki Yamanouchi; Eiko Hasegawa; Naoki Sawa; Ryoji Takei; Kenmei Takaichi; Yoshifumi Ubara
Journal:  J Nephrol       Date:  2014-09-18       Impact factor: 3.902

7.  Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial.

Authors:  Sawako Kato; Shoichi Maruyama; Hirofumi Makino; Jun Wada; Daisuke Ogawa; Takashi Uzu; Hisazumi Araki; Daisuke Koya; Keizo Kanasaki; Yutaka Oiso; Motomitsu Goto; Akira Nishiyama; Hiroyuki Kobori; Enyu Imai; Masahiko Ando; Seiichi Matsuo
Journal:  Clin Exp Nephrol       Date:  2015-03-21       Impact factor: 2.801

Review 8.  The necessity and effectiveness of mineralocorticoid receptor antagonist in the treatment of diabetic nephropathy.

Authors:  Atsuhisa Sato
Journal:  Hypertens Res       Date:  2015-03-12       Impact factor: 3.872

9.  Comparison of prognosis between patients with renal cell carcinoma on hemodialysis and those with renal cell carcinoma in the general population.

Authors:  Yasunobu Hashimoto; Toshio Takagi; Tsunenori Kondo; Junpei Iizuka; Hirohito Kobayashi; Kenji Omae; Kazuhiko Yoshida; Kazunari Tanabe
Journal:  Int J Clin Oncol       Date:  2015-03-12       Impact factor: 3.402

10.  Interactive Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers or Their Combination on Survival of Hemodialysis Patients.

Authors:  Ryo Kido; Tadao Akizawa; Masafumi Fukagawa; Yoshihiro Onishi; Takuhiro Yamaguchi; Shunichi Fukuhara
Journal:  Am J Nephrol       Date:  2017-11-21       Impact factor: 3.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.